Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRLF2 -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy

1 Oct 2024

Abstract excerpt

Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with KMT2A rearrangements following chemotherapy, but is now increasingly being observed as a form of immune escape following targeted therapies among children and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39461880
DOI: 10.1136/jitc-2024-009499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRLF2 -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapyPMID 39461880Read ↗

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switchSemantic proximity Read ↗

Genetics and pathologic landscape of lineage switch of acute leukemia during therapySemantic proximity Read ↗

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapySemantic proximity Read ↗

To B‐ or not to B‐: A review of lineage switched acute leukemiaSemantic proximity Read ↗

Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin.Semantic proximity Read ↗

Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL PatientsSemantic proximity Read ↗

Genetics and Pathologic Landscape of Lineage Switch of Acute Leukemia during Therapy: A Multi-institutional StudySemantic proximity Read ↗

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomabSemantic proximity Read ↗

The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patientsSemantic proximity Read ↗

Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemiaSemantic proximity Read ↗

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysisSemantic proximity Read ↗

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.